Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Robin Garner is an analyst at Craig-Hallum. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2025
Buy Now | Get Alert | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
08/28/2023 | XERS | Buy Now | Xeris Biopharma Holdings | $4.83 | -6.83% | Robin Garner26% | → $4.5 | Initiates | → Buy | Get Alert |
04/28/2022 | XERS | Buy Now | Xeris Biopharma Holdings | $4.83 | 34.58% | Robin Garner26% | → $6.5 | Initiates | → Buy | Get Alert |
03/18/2022 | CUE | Buy Now | Cue Biopharma | $0.69 | 3681.82% | Robin Garner26% | $28 → $26 | Maintains | Buy | Get Alert |
10/20/2021 | LABP | Buy Now | Landos Biopharma | — | — | Robin Garner26% | → $45 | Initiates | → Buy | Get Alert |
08/24/2021 | TRIL | Buy Now | Trillium Therapeutics | — | — | Robin Garner26% | $21 → $18.5 | Downgrade | Buy → Hold | Get Alert |
08/02/2021 | FMTX | Buy Now | Forma Therapeutics Hldgs | — | — | Robin Garner26% | → $58 | Initiates | → Buy | Get Alert |
04/21/2021 | FENC | Buy Now | Fennec Pharmaceuticals | $7.55 | 125.17% | Robin Garner26% | → $17 | Initiates | → Buy | Get Alert |
08/17/2020 | TRIL | Buy Now | Trillium Therapeutics | — | — | Robin Garner26% | → $15 | Initiates | → Buy | Get Alert |